title: Up-regulation of peripherin is associated with alterations in synaptic plasticity in CA1 and CA3 regions of hippocampus.
abstract: Peripherin is a type III intermediate filament protein normally undetectable in most brain neurons. Here, we report a similar pattern of peripherin expression in the brains of both mice treated with systemic injections of kainic acid (KA) and in peripherin transgenic mice (Per mice) over-expressing the normal peripherin gene under its own promoter. Double-immunofluorescence labeling revealed a partial co-localization of peripherin with the microtubule-associated protein MAP2, but not with neurofilament proteins. Electrophysiological studies revealed that synaptic plasticity was markedly altered in Per mice: in CA1, long-term potentiation (LTP) was decreased in Per slices (+29 +/- 2.0%, vs. +58 +/- 5.4%, in WT); while in CA3, LTP was increased in Per (+63 +/- 3.5% vs. +43 +/- 2.4.0%). In the hippocampus of Per mice, the levels of MAP2 were decreased, though synaptophysin and PSD95 remained unchanged. These intriguing findings suggest a role of peripherin in the alteration of hippocampal synaptic plasticity.
authors.affiliation: Centre Hospitalier de l'Universite Laval Research Center, Quebec City, Quebec, Canada. Jasna.Kriz@crchul.ulaval.ca
authors.forename: Jasna
authors.initials: J
authors.lastname: Kriz
authors.forename: Jean-Martin
authors.initials: JM
authors.lastname: Beaulieu
authors.forename: Jean-Pierre
authors.initials: JP
authors.lastname: Julien
authors.forename: Kresimir
authors.initials: K
authors.lastname: Krnjević
mesh_terms: D000818:Animals; D030801:Animals, Genetically Modified; D001522:Behavior, Animal / Q000502:physiology; D004195:Disease Models, Animal; D015536:Down-Regulation / Q000187:drug effects / Q000235:genetics; D004827:Epilepsy / Q000139:chemically induced / Q000378:metabolism* / Q000503:physiopathology; D005455:Fluorescent Antibody Technique; D015870:Gene Expression / Q000187:drug effects / Q000502:physiology; D020022:Genetic Predisposition to Disease; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism* / Q000503:physiopathology; D007381:Intermediate Filament Proteins / Q000235:genetics / Q000378:metabolism*; D007608:Kainic Acid; D017774:Long-Term Potentiation / Q000235:genetics; D008562:Membrane Glycoproteins / Q000235:genetics / Q000378:metabolism*; D051379:Mice; D008869:Microtubule-Associated Proteins / Q000378:metabolism; D009419:Nerve Tissue Proteins / Q000235:genetics / Q000378:metabolism*; D009473:Neuronal Plasticity / Q000235:genetics*; D009924:Organ Culture Techniques; D064531:Peripherins; D011401:Promoter Regions, Genetic / Q000187:drug effects / Q000235:genetics; D009435:Synaptic Transmission / Q000235:genetics*; D016708:Synaptophysin / Q000378:metabolism; D013788:Thalamus / Q000378:metabolism / Q000503:physiopathology; D015854:Up-Regulation / Q000187:drug effects / Q000235:genetics
chemical_list: D007381:Intermediate Filament Proteins; D008562:Membrane Glycoproteins; D008869:Microtubule-Associated Proteins; C079240:Mtap2 protein, mouse; D009419:Nerve Tissue Proteins; D064531:Peripherins; D016708:Synaptophysin; D007608:Kainic Acid